Member Info for crumbs

Sounds quite confident that a deal will come from the Glycan/AvidiMab collabs later this year 'translate into transactions'

The main thing he was there... and got a discount due to BIA... maybe they all had to bunk together at the YHA too... every penny counts and they are very careful with cashburn after all :)

I suppose attending as part of the BIA delegation would be more accurate but it is them that mention 'presenting'... Anyways hopefully Cliff is totally knackered now after all the meetings and attention and is just deciding on whos $$billions to accept :)

I was going off the BIA tweet...https://twitter.com/BIA_UK/status/1226838265828913152

Following their exciting US IND announcement,BIA member Scancell present @IAmBiotech's CEO & Investor Conference.

Or something like that

WTP sorry... It's chat about a different bio

That could be quite a dramatic event!....

To stir that old pot that has been well stirred in the past... but just had a look in on our old friends over in that other tiny AIM bio I once was lucky to escape from with a tiny profit and wow... down the tubes it seems to be going as a yoda might say! .... it really is a shame what is happening there and a lesson to all pi's ... Certainly, the coming in of and strong support from Vulpes last year was the most pivotal and vital thing to keep scancell from falling into such murky waters ... let us hope Cliff has been having success over in the states and some further positive newsflow gets our sp back over 10p where it belongs, still hopeful of a positive TCR update resulting in a BioNTech licensing deal.

Almost like the IND news has lifted an anchor

Won't they need to try again but this time comply with German laws?.... I don't know ... Be interesting to hear from anyone who is clued up on such matters...

Yeah, it is strange ... Obviously it has caused a stir of speculation as in could they be about to be taken over... I do not think so though more likely they messed up and have enough money for now... Surely they will need more sometime soon with the amount they burn through

Withdrew its placing last Friday which was a bit strange.... Anyways this is the reason given.... note its a web translation from German:

'Last week, the biotech company BioNTech, based in Mainz, announced that it would like to place a share. The plan was to issue up to 6.9 million American Depositary Shares (ADS), which represent the company's own ordinary shares. However, the surprising cancellation came on Friday. There was direct speculation on the market. Biotech experts Michel Doepke and Marion Schlegel asked the company directly what the reasons were. Here is the answer from BioNTech.

“The order book was fully drawn. As a German company, we are also subject to German securities regulations, which limit the clearing price. While the US regulations do not limit discounts, there is a 5% limit in German law. This also applied to our closing course on February 5, 2020. BioNTech's Management Board and Supervisory Board have therefore decided that it is in the best interest of the company and the existing shareholders not to carry out the transaction.'

Also, I'm sure Martin Diggle would be accommodating in helping to get in any interested US investors which is another added attraction to the investment case

There are some unknowns too... The modi1 trial, in theory, has just gotten more expensive with the adding of Renal Cancer to the previous 3 targets... why?... obviously clinically there is a reason as Renal has always looked to be a good potential responding target but does that outweigh the added costing in factor?... Or could someone be just waiting for that final manufacturing hurdle to be jumped over before coming in as a partner? .... BMS the owners of Pembro that is to be used in combo with modi1 in at least one target group.... We know are interested in the science around moditope as they bought out Padlock theraputics which uses similar science to target RA

I think your timescales are going to be about right...By April/May the coffers could do with a topping up... Obviously I hope something with BioNTech may be concluded by then as the 6-month collaboration delay there ought to have been eaten up by then ...The other thing is I hope we do not need to rely too heavily on Vulpes and someone or others also come in Cliff is in the US no doubt working to that end... A US investor would be most welcome and with all that is going on at scancell , US IND a partnership with NASDAQ listed new star BioNTech and Avidimab attracting such interest and of course being able to name drop the No1 US melanoma clinician Keith Flaherty and possibly MD Anderson too... I think even me and you could flog the case for scancell there lol

What I think we can still conclude is ... Cancer is one hard mother of a monster to fully defeat.... no matter what the advances ...personally I think BioNTech are looking at it the right way each patient ought to be treated personally with a complete personalised treatment plan involving multiple treatments ...... Germans eh

I think a lot of issues can be raised here.. some were mentioned in that Allison interview... And I do not think we can underestimate the value of the recent news of Lindy getting access to bloods and tumour samples from the cancer survivors whos immune systems somehow kick in at the last minute and overcome terminal disease

No, I doubt it, as the trial is finished and as we know scancell themselves knew nothing about Toms passing from his disease the trial was a success a majority of patients especially resected went over the 5-year survival benchmark ... Which yes you can say is a bit strange when patients go on to still succumb to melanoma... however again that is the reality of late-stage melanoma

It's not me questioning the ethics that was Jim Allison though I agree with him..... We are still in very very pioneering territory... His own 'Ipi' at best 20% success and that success can be questioned too with side effects etc however it does indeed work people who were doomed now have a chance.... Yes combining different CI's has raised the bar but that bar is still far too low and SCIB1 is not a CI its mode of effectiveness is different ... Which makes SCIB1 a potentially effective synergistic combo for CI's.... why not have a triple combo? Ipi and pembro and SCIB for instance ... The sad news about Tom brings into focus the need for better treatments and more data! We have no idea which one of scancells SCIB1 trial patients he was.... could he have been one who was to be on the continuation arm that sadly never happened due to SCIB1 going out of date we cannot know but as far as we know everyone on the trial who got a therapeutic dose had an immune response and that is important especially as that immune response is different from a CI one.....

The sun has actually now made an appearance up here